2026-10-27

Your essential 340B program update.

Recent legal and legislative developments surrounding the 340B rebate pilot have intensified scrutiny of the program. The American Hospital Association and other stakeholders have filed a lawsuit to block the pilot, citing potential costs exceeding $1 billion. In response, major drug manufacturers, including AbbVie and Bristol Myers Squibb, have sought to intervene in the case. Concurrently, a bipartisan federal bill has been introduced to delay the pilot’s implementation by two years, mandating upfront discounts until the end of 2028. An HHS report has also criticized the expansion of the 340B program, arguing that it prioritizes hospital profits over patient care. As compliance requirements for the rebate pilot are detailed, operational questions continue to arise about the contentious nature of this initiative and its implications for healthcare providers and patients.

EXECUTIVE SUMMARY
01
Hospitals sue to block 340B rebate pilot.
The American Hospital Association and others filed a lawsuit to halt the 340B rebate pilot, citing over $1 billion in potential costs.

02
Drugmakers seek to join 340B lawsuit.
AbbVie, Bristol Myers Squibb, and others filed motions to intervene in the lawsuit against HRSA’s 340B rebate pilot.

03
Federal bill proposes 340B rebate pilot delay.
A bipartisan bill aims to delay the 340B rebate pilot by two years, requiring upfront discounts until the end of 2028.

04
HHS report criticizes 340B program expansion.
An HHS report claims the 340B program prioritizes hospital profit over patient care, citing spread pricing concerns.

Source: TechTarget

05
340B rebate pilot compliance requirements detailed.
HRSA outlines compliance requirements for the 340B rebate pilot, requiring claims-level data submission.

Source: MENAFN

06
Legal challenges to 340B rebate pilot intensify.
Multiple lawsuits and motions to intervene show the contentious nature of the 340B rebate pilot’s implementation.

Source: STAT News

EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal challenges and proposed legislative delays regarding the 340B rebate pilot signal a critical moment for covered entities. If the pilot proceeds as planned, hospitals and other entities may face significant financial burdens due to the anticipated costs associated with compliance and potential loss of revenue. The pushback from both hospitals and drug manufacturers reflects the complexities of the 340B program and its impact on patient care. Covered entities must address these challenges carefully, as the outcome of these legal disputes and legislative actions could reshape their operational strategies and financial viability in the coming years.
Emerging risks.

  • Hospitals face potential cash flow issues under the 340B rebate pilot, impacting patient care funding.
  • The CMS proposed payment cuts could reduce hospital revenues by billions, affecting service provision.
  • Legal challenges to the rebate pilot may delay or alter its implementation, creating uncertainty.
  • Drugmakers’ intervention in the lawsuit could complicate legal proceedings and outcomes.
  • The HHS report details risks of program misuse, potentially leading to stricter regulations.
Emerging opportunities.

  • Hospitals can engage with lawmakers to influence the outcome of the proposed 340B rebate delay bill.
  • Covered entities may improve transparency and compliance through claims-level data submission.
  • Drugmakers have a chance to defend their rebate plans in court, potentially shaping future policy.
  • The CMS repository is a platform for testing data submissions, aiding compliance efforts.
  • HRSA’s pilot findings could inform future 340B program changes and policy decisions.
Key actions for providers.

  • Hospitals should prepare for potential operational changes under the 340B rebate pilot.
  • Engage in advocacy efforts to support or oppose the proposed 340B rebate delay legislation.
  • Monitor legal proceedings closely to anticipate impacts on the 340B program.
  • Review and update compliance systems to meet HRSA’s rebate pilot requirements.
  • Collaborate with stakeholders to address concerns raised in the HHS report on 340B program expansion.
TOP STORIES
Hospitals sue to block 340B rebate pilot.
Becker’s Hospital Review · October 9, 2026
  • The AHA and others filed a lawsuit on October 9 to halt the 340B rebate pilot.
  • Hospitals argue the pilot imposes over $1 billion in annual administrative costs.
  • The lawsuit challenges replacing upfront discounts with post-sale rebates.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
Federal bill proposes 340B rebate pilot delay.
Becker’s Hospital Review · October 13, 2026
  • The bill would delay the 340B rebate pilot until December 31, 2028.
  • It requires upfront discounts during the delay period.
  • The bill aims to allow Congress time to consider broader 340B reforms.
HHS report criticizes 340B program expansion.
TechTarget · October 12, 2026
  • The report claims the 340B program prioritizes profit over patient care.
  • It raises concerns about spread pricing and program growth.
  • The report suggests potential regulatory changes to address these issues.
340B PROGRAM DEVELOPMENTS
340B rebate pilot’s operational questions arise.
Becker’s Hospital Review · October 26, 2026
  • Hospitals will pay full price for 21 drugs starting January 1, 2027.
  • Rebates will replace upfront discounts under the new model.
  • HRSA approved plans from 10 drugmakers for the pilot.
340B rebate pilot compliance requirements detailed.
MENAFN · October 20, 2026
  • Covered entities must submit claims data within 45 days of dispense.
  • Manufacturers must pay or deny rebates within 10 days of submission.
  • HRSA will incorporate compliance into its audits of covered entities.
STATE DEVELOPMENTS
Washington: 340B Carve-In Policy Implemented.
Washington State Health Care Authority 340B Drug Pricing Program · October 23, 2026
  • Washington State Health Care Authority requires covered entities to determine if they will participate and use 340B purchased drugs for Apple Health patients, a practice known as “carving-in.”
  • Covered entities must bill the state at Actual Acquisition Cost (AAC) for fee-for-service claims.
  • Washington does not support 340B contract pharmacies; drugs purchased under 340B can only be billed to the agency by the PHS-qualified entities themselves.
LITIGATION & ENFORCEMENT WATCH
Court Matter Date
D. Me. AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Brief of Amici Curiae by 340B health, america’s essential hospitals, association of american medical colleges, children’s hospital association. Case filed October 9, 2026. [source] October 20, 2026
M.D. Fla. Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] October 14, 2026
S.D.N.Y. Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] October 13, 2026
D.N.H. Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] October 6, 2026
WHAT TO WATCH NEXT
  • Monitor the outcome of the lawsuit against the 340B rebate pilot in the District of Maine. [source]
  • Watch for Congressional action on the 340B Rebate Model Delay Act. [source]
  • Track HRSA’s interim summaries of the 340B rebate pilot findings due by April 30, 2028. [source]
  • Follow CMS’s proposed rule on 340B drug payment cuts, effective January 1, 2027. [source]
End of briefing.

This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.

© 2026 MedMatrix Rx. All rights reserved.

Post information

Schedule Your 340B Assessment

Connecting healthcare organizations to their full potential through compliant 340B optimization.